GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (AMEX:LCTX) » Definitions » Intangible Assets

Lineage Cell Therapeutics (Lineage Cell Therapeutics) Intangible Assets : $57.21 Mil (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lineage Cell Therapeutics Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Lineage Cell Therapeutics's intangible assets for the quarter that ended in Mar. 2024 was $57.21 Mil.


Lineage Cell Therapeutics Intangible Assets Historical Data

The historical data trend for Lineage Cell Therapeutics's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Intangible Assets Chart

Lineage Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.92 57.70 57.49 57.36 57.23

Lineage Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.33 57.30 57.27 57.23 57.21

Lineage Cell Therapeutics Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Lineage Cell Therapeutics  (AMEX:LCTX) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Lineage Cell Therapeutics Intangible Assets Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Lineage Cell Therapeutics (Lineage Cell Therapeutics) Business Description

Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Executives
Anula Jayasuriya director 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Jill Ann Howe officer: Chief Financial Officer C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Dipti Amin director C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Brian M Culley director, officer: President and CEO 6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Gary S. Hogge officer: SVP,Clinical & Medical Affairs 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Samuel George A. Iii officer: General Counsel/Secretary C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kevin Leon Cook officer: Chief Financial Officer C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Alexandra Hernandez officer: Sr Director Finance/Controller C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Brandi Roberts officer: CFO & SVP, Finance 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Edward Wirth officer: Chief Medical Officer C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Don M Bailey director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607

Lineage Cell Therapeutics (Lineage Cell Therapeutics) Headlines

From GuruFocus